Description
Today on MedNet21, we're going to discuss New Therapies for Type 2 Diabetes.
Insulin has been used for almost 100 years and non-insulin diabetes medications since 1946, but over the last few years there have been a flurry of new therapies. These new medications have focused on two main targets: 1) reducing hypoglycemia and 2) decreasing cardiovascular disease, the leading cause of mortality in type 2 diabetes.
Dates and Times
End Date: 2/1/2022
Objectives
As a result of this educational activity, webcast participants will be able to: DESCRIBE the role of new medical therapies in hypoglycemia; and DESCRIBE the role of new medical therapies in cardiovascular disease.
You’ll also learn about the following:
- New directions in the treatment of type 2 diabetes
- Hemoglobin A1C targets
- Treatment of type 2 diabetes when medication cost is a consideration
- New glucose monitoring technologies
Webcasts Files
Webcasts Links
| Title | Link |
|---|---|
|
Listen to Audio Only CME Podcasts |
View Link |
Speakers
Accreditation
The Center for Continuing Medical Education (CCME) at The Ohio State University is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians
The Center for Continuing Medical Education (CCME) at The Ohio State University designates this webcasts for a maximum of 1.00 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.